Bratha

Part 4.1 — When the Numbers Move

15 min read

This is Part 4.1 of 5 in the Performance Enhancement Series — the "Tier 3" continuation of the Fitness Series' Pharmacology chapter. The full path:

Table of Contents

Framing

This is the response manual for a marker that’s drifted the wrong way: what it means, where it leads, and what to do. It is harm-reduction education, not medical advice. The interventions include prescription medications (see Part 4.0) that require a physician. Acute or severe readings — a hypertensive crisis, chest pain, a flagged arrhythmia, severe shortness of breath — are emergencies, not troubleshooting items. Seek care.

The health-side decision tree

Part 1.1 gave you a diagnostic decision tree for training: a symptom (the scale stalls, strength drops), a diagnosis, and an action. That tree turned training from guesswork into a system. This article is the exact same tool, pointed at your health markers instead of your physique.

Part 2.0 and Part 2.1 taught you to measure. Part 4.0 taught you the mechanisms and the toolbox. Part 4.1 is where they meet: a specific number moves, and you work the tree — mechanism, trajectory, response — instead of panicking or, worse, ignoring it. Every entry below ends in the same place the meta-rule does: if the ladder doesn’t fix it, the dose comes down.

How to read this

Each marker follows one structure, deliberately echoing Part 1.1:

  • What moved — the reading and direction.
  • What’s happening — the mechanism (the deep version lives in Part 4.0).
  • Where it leads — the trajectory if you ignore it.
  • The response ladder — worked top to bottom: (1) confirm it’s real → (2) fix the obvious cause (free lifestyle levers) → (3) adjust the protocol (dose, compound, frequency) → (4) add a super ancillary (with a physician — which member of the family to pick is Part 4.2) → (5) the pull-back trigger (when the answer is “less, or off”).

The ladder always runs in order

The reflex on a bad number is to reach for a drug to mask it. The professional reflex is to climb the ladder: confirm, then cause, then protocol, then pharmacology — and to treat step 5 as a real option, not a failure. A marker is data about your dose, not an obstacle to your dose.

The cardiovascular cluster

This is the cluster that actually kills people (Part 1, Part 4.0),1 so it comes first and gets the most weight. Notice how many entries converge.

Blood pressure ↑

  • What’s happening: sodium/water retention via mineralocorticoid and RAAS activation, plus rising blood volume and hematocrit — the Part 4.0 mechanism.
  • Where it leads: left ventricular hypertrophy, kidney and retinal damage, stroke. Over 180/120 on a confirmed repeat is a hypertensive emergency — care now.
  • The ladder:
    1. Confirm — rested 5 min, correct cuff (wrist if your arms are over ~46 cm, per Part 2.1), repeat.
    2. Cause — sodium/potassium balance, hydration, stimulants, sleep, stress.
    3. Protocol — lower the dose; smooth peaks with injection frequency; check estradiol (water) and hematocrit.
    4. Super ancillary — telmisartan/nebivolol; tadalafil pulls double duty here (Part 4.0). Physician only.
    5. Pull-back trigger — BP that won’t hold under ~140/90 despite all of the above.

Lipids: HDL ↓ / LDL & ApoB ↑

  • What’s happening: AAS upregulate hepatic lipase, gutting HDL and shifting LDL to small, dense particles — worst with oral 17-alkylated compounds and crashed estrogen (Part 4.0).
  • Where it leads: accelerated atherosclerotic plaque → the heart attack that takes shredded lifters at 40.
  • The ladder:
    1. Confirm — fasted draw; track ApoB, not just LDL.
    2. Cause — moderate saturated fat on harsh cycles; keep doing cardio.
    3. Protocol — minimize/shorten orals; don’t crash E2 (Pathway 3); omega-3 + citrus bergamot.
    4. Super ancillary — statin (HMG-CoA) ± ezetimibe (NPC1L1); Cardarine helps the panel (Part 4.0). Physician only.
    5. Pull-back trigger — HDL into single digits or ApoB climbing despite intervention = the orals/dose are the problem.

Hematocrit / blood viscosity ↑

  • What’s happening: androgens stimulate red-cell production; the blood thickens.
  • Where it leads: clots, stroke, cardiac strain — and it silently drives BP and the RHR/HRV drift below.
  • The ladder:
    1. Confirm — hydrate before the draw (dehydration falsely inflates it, per Part 2.0).
    2. Cause — chronic dehydration, sleep apnea (see below).
    3. Protocol — lower the androgen dose.
    4. Super ancillary — therapeutic phlebotomy / blood donation as it approaches 52–54%;[^4] low-dose aspirin for clot risk, physician-guided.
    5. Pull-back trigger — hematocrit needing repeated phlebotomy to stay in range = dose too high.

Resting HR ↑ / HRV ↓

  • What’s happening: your cheapest early-warning (Apple Watch). A rising resting heart rate and falling HRV reflect systemic strain — cardiovascular load, thick blood, under-recovery, illness, or climbing BP — often days before a cuff or a blood draw would confirm it.2
  • Where it leads: it’s a signal, not a disease — but a sustained wrong-way trend is the canary for everything else in this cluster.
  • The ladder:
    1. Confirm — trend over days, not one bad night; same conditions.
    2. Cause — sleep, stress, alcohol, illness, training load.
    3. Protocol — if it tracks with dose escalation, that’s your answer; check hematocrit and BP.
    4. Super ancillary — none directly; treat the marker it points to.
    5. Pull-back trigger — a recovery score that stays in the floor despite good sleep = deload and reassess the protocol.

Irregular rhythm / ECG flag

  • What’s happening: long-term AAS raise arrhythmia and atrial-fibrillation risk; the single-lead ECG can flag possible AFib.
  • Where it leads: clot and stroke risk. This one skips the ladder.
  • The response: a flagged irregular rhythm — or palpitations, syncope, chest pain — goes to a cardiologist, now. It is not a lifestyle tweak.

Cardio fitness (VO₂max estimate) ↓

  • What’s happening: the Apple Watch estimate drifting down means the heart is working harder for the same output and the aerobic base is eroding.
  • Where it leads: reduced cardiovascular resilience across the cycle — and a measurable hit to the Endurance benchmark.
  • The ladder: confirm the trend → keep zone-2 cardio in the program (the non-negotiable cardioprotection from Part 4.0) → check BP/hematocrit → if it keeps falling, the load is outrunning your recovery.

The metabolic cluster

Fasting glucose / HbA1c ↑

  • What’s happening: GH (and insulin, if used) impair insulin sensitivity (Pathways 7 & 8); glucose creeps up.
  • Where it leads: pre-diabetes, type-2 diabetes, and the vascular/nerve damage that compounds every other cardiovascular front.
  • The ladder:
    1. Confirm — true fast; glucometer for daily trend, HbA1c for the 3-month average.
    2. Cause — carbohydrate quality/timing, body-fat creep, cardio.
    3. Protocol — reduce GH/secretagogue dose; berberine.
    4. Super ancillary — SGLT2 inhibitor or metformin, physician-guided (Part 4.0).
    5. Pull-back trigger — HbA1c climbing into pre-diabetic range = the GH/insulin load is too high.

Body weight ↑ suddenly

  • What’s happening: a fast few-kilo jump isn’t tissue — it’s water, usually estrogen-driven (Pathway 3) or electrolyte instability (Part 3.2).
  • Where it leads: it’s also an early blood-pressure warning — water retention pushes BP up.
  • The ladder: confirm against the weight-trend graph (is strength tracking it? then it’s tissue) → stabilise electrolytes and check E2 → adjust AI/injection frequency → if it’s compound-driven bloat (high-dose 19-nor RAAS), that’s a protocol problem, not a diuretic problem.

Basal body temperature ↓

  • What’s happening: months of caloric deficit downregulate thyroid output (BBT drifts toward 36.5 °C); GH accelerates T4→T3 conversion, so the thyroid picture shifts on cycle too.
  • Where it leads: a stalled cut, metabolic adaptation, low energy — the diet-fatigue diagnosis with a hormonal floor under it.
  • The ladder: confirm with morning BBT + the thyroid triad (TSH, fT3, fT4) → diet break / refeed, adequate iodine/selenium → only then consider thyroid hormone, physician-guided → don’t “push through” a downregulated metabolism with more stimulants.

The hormonal cluster

Estradiol — too high or too low

  • What’s happening: aromatization of your test base raises E2; over-zealous AI use crashes it. Both are problems (Pathway 3).
  • Where it leads: high → water, blood pressure, gyno risk; low → joint pain, dead libido, low mood, brittle lipids, blunted gains. Crashed estrogen is as much a failure state as high estrogen.
  • The ladder: confirm with a sensitive assay3 → manage with injection frequency first → use the minimum AI only if genuinely high → a DHT derivative (Masteron/Proviron) can modulate aromatization without an AI (Part 3.2) → target “in range,” never “as low as possible.”

Prolactin ↑

  • What’s happening: heavy 19-nors (nandrolone, trenbolone) raise prolactin via the progesterone pathway — even with E2 controlled.
  • Where it leads: killed libido, gyno that an AI won’t fix, broader sexual dysfunction.
  • The ladder: confirm on bloods → P5P (vitamin B6) and vitamin E first → reduce/remove the 19-nor → cabergoline only for significant elevation, physician-guided (and itself an argument against heavy 19-nors) → if you need cabergoline to tolerate the compound, the compound is the problem.

SHBG too low

  • What’s happening: oral abuse crushes SHBG — but the SHBG-receptor complex is a carrier that delivers androgens to tissue, not just a “sponge.”
  • Where it leads: diminished libido and, paradoxically, impaired anabolism despite high free testosterone.
  • The ladder: confirm on the hormone panel → ease off orals; eat enough (chronic under-eating distorts it) → keep it above ~20 nmol/L → don’t chase “lowest possible SHBG.”

LH / FSH / testosterone (the HPTA, post-cycle)

  • What’s happening: exogenous androgens suppress LH and FSH; coming off, you’re in an androgen-deficient state until the axis restarts.
  • Where it leads: low testosterone, low mood, fat gain, lost strength — and, if it doesn’t recover, the TRT-for-life fork.
  • The ladder: HCG on cycle to preserve testicular function → SERM-based PCT (tamoxifen/clomiphene) to restart → re-test LH/FSH/total & free testosterone ~4–8 weeks post-PCT (Part 2.0) → if recovery stalls repeatedly, that’s the blast-and-cruise vs. calendar-cycling decision made for you.

Cortisol ↑

  • What’s happening: elevated cortisol signals overtraining or sympathetic-nervous-system burnout — and it’s catabolic, the thing the glucocorticoid pathways try to block.
  • Where it leads: muscle loss, poor recovery, the environmental-burnout state.
  • The ladder: confirm (morning, fasted) → sleep, deload, manage life stress, intra-workout carbs → ashwagandha/phosphatidylserine → if it stays high, you’re overreaching: pull training and pharmacological intensity back (cycle by the calendar).

The organ cluster

Liver enzymes (GGT, with ALT/AST) ↑

  • What’s happening: oral 17-alkylated steroids stress the liver. But AST/ALT are also raised by training and creatine, so GGT and bilirubin are the cleaner read (Part 2.0).
  • Where it leads: cholestasis and hepatic strain — concentrated almost entirely in oral users.
  • The ladder: confirm with the 7-day no-training rule before the draw, read GGT → no alcohol; TUDCA/NAC → shorten/limit the oral → if GGT/bilirubin keep climbing, the oral comes out. Injectable testosterone is comparatively liver-friendly.

Kidney (cystatin C ↑ / eGFR ↓)

  • What’s happening: kidneys take collateral damage from high BP, very high lean mass, dehydration, and harsh compounds. Use cystatin C — creatinine over-reads in muscular athletes (Part 2.0).
  • Where it leads: declining filtration, compounding with hypertension.
  • The ladder: confirm with cystatin-C-based eGFR → hydrate, control BP (the biggest renal lever) → ease NSAIDs/high-dose creatine/harsh compounds → falling eGFR despite BP control = reduce the load and involve a physician.

SpO₂ ↓ / heavy snoring

  • What’s happening: significant mass gain (neck/tissue) raises sleep-apnea risk; the wearable overnight SpO₂ dip or a partner’s report is the flag.
  • Where it leads: wrecked recovery, daytime fatigue, and added cardiovascular strain that feeds BP and hematocrit.
  • The ladder: confirm → get a sleep study → CPAP and weight/water management → untreated apnea sabotages every other marker in this article.

The master diagnostic tree

Marker movedMost likely causeIf ignoredFirst actionEscalation (Rx)Pull-back trigger
BP ↑Water/RAAS, hematocrit, E2, doseLVH, stroke, kidneyElectrolytes, hydration, sleepTelmisartan / tadalafilWon’t hold <140/90
HDL ↓ / ApoB ↑Hepatic lipase (orals), low E2Plaque → MICut orals, omega-3, cardioStatin ± ezetimibeHDL single digits
Hematocrit ↑Androgen-driven RBCClot, strokeHydratePhlebotomy, aspirinNeeds repeat phlebotomy
RHR ↑ / HRV ↓Systemic strainCanary for the clusterSleep, deload(treat the cause)Floor recovery despite sleep
ECG irregularArrhythmia/AFib riskStroke—Cardiologist nowAny flag
Glucose/HbA1c ↑GH/insulin resistanceDiabetesCarbs, cardio, berberineSGLT2 / metforminPre-diabetic A1c
Sudden weight ↑Water (E2/electrolytes)BP riseElectrolytes, E2 check(AI / frequency)Compound-driven bloat
Basal temp ↓Thyroid downregulationStalled cutDiet break, iodine/SeT3/T4 (MD)—
E2 high or lowAromatization / AI abuseBoth harmfulInjection frequencyMinimum AISymptoms persist
Prolactin ↑19-norsLibido, gynoP5P, vit ECabergolineNeeds caber to tolerate
SHBG too lowOral abuseLibido, anabolismCut orals, eat enough—<20 won’t recover
LH/FSH/Test ↓ (off)HPTA suppressionTRT-for-lifeHCG, SERM PCT—Repeated failed recovery
Cortisol ↑Overtraining/burnoutMuscle lossSleep, deload, carbsAshwagandha/PSStays high → pull back
GGT ↑Oral hepatotoxicityCholestasisNo alcohol, TUDCA—Won’t fall → orals out
Cystatin C ↑BP, mass, dehydrationRenal declineHydrate, control BP—eGFR keeps falling
SpO₂ ↓ / snoringSleep apnea (mass)CV strainSleep studyCPAP—

The meta-rule: the cycle serves the markers

Every ladder in this article ends at the same rung, and it’s worth making explicit because it’s the hardest one to actually pull:

Blood work is the final arbiter

When a marker won't return to range despite confirming it, fixing the cause, adjusting the protocol, and adding the right ancillary, the answer is not a stronger ancillary — it's less drug, or none. The cycle exists to serve your long-term markers, not the other way around. This is Part 1’s “you only have so many blasts” and Part 3.2’s “cycle by the calendar” expressed as a single reflex: the number is the boss.

The athletes who last aren’t the ones who out-medicate their bloodwork. They’re the ones who treat a stubborn marker as information — this dose, this compound, is costing more than it’s worth — and act on it while it’s still a number on a screen and not a diagnosis in a clinic.

This is where the series lands

Decide → Screen → Monitor → Optimize → Protect → respond. If you’ve read this far, you have the whole loop. The point was never a protocol — it’s the reasoning to run your own, measured and intact. Take whatever's useful. Ignore whatever isn't.

Part 4.1 Takeaways

Key concepts to internalize

  • It’s a decision tree, not a panic button. Every marker has a mechanism, a trajectory, and a worked response — the health-side version of Part 1.1’s training tree.
  • Run the ladder in order: confirm → cause → protocol → super ancillary → pull back. Don’t skip to the drug.
  • The cardiovascular cluster converges. BP, lipids, hematocrit, RHR/HRV all feed one another — fix upstream (dose, hematocrit, E2) and several improve at once.
  • Two markers skip the ladder. A flagged arrhythmia and a hypertensive crisis are emergencies — physician/ER, immediately.
  • High and low are both failure states. Crashed estradiol and crushed SHBG are as bad as the high versions — target “in range,” not “as low as possible.”
  • The number is the boss. A marker that won’t normalize is telling you the dose or compound is too costly. Believe it.

Your Diagnostic Task List

  1. Build the master tree into your tracking sheet next to your checkpoints and device trends, so a moving number has an immediate response.
  2. Pre-decide your pull-back triggers — write the specific values (HDL, BP, hematocrit, HbA1c) at which you’ll lower the dose, before you’re emotionally invested in a cycle.
  3. Know your two emergencies cold: BP >180/120 confirmed, and any flagged irregular rhythm → care now.
  4. Pair every device trend with its confirmer — a wearable RHR/HRV drift means take a cuff reading and book bloods, not act blindly.
  5. Line up your physician for the escalation rungs (statin/ezetimibe, SGLT2, telmisartan, tadalafil, cabergoline) before you need them.
  6. Re-read Part 1. The willingness to pull back on a bad marker is the same maturity that decided whether to start at all.

Disclaimer

This article is harm-reduction education, not medical advice. Interpreting markers and choosing interventions requires a qualified physician — reference ranges, assays, and clinical context vary, and one number means different things in different people. The interventions referenced include prescription medications with serious risks and interactions; do not self-prescribe. The performance-enhancing compounds discussed are prescription-only or illegal without a prescription in most jurisdictions, including Malaysia. Seek emergency care for a hypertensive crisis (over 180/120), chest pain, fainting, severe shortness of breath, or a flagged irregular heart rhythm.

Sources & references

Footnotes

  1. Cardiovascular toxicity of long-term AAS use (adverse lipids, hypertension, erythrocytosis, LVH/diastolic dysfunction, and arrhythmia/atrial-fibrillation risk): Baggish et al. (2017), Circulation, “Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use.” The full mechanistic chains (hepatic lipase → dyslipidemia; ApoB → atherosclerosis; RAAS → hypertension) and the intervention pharmacology are detailed and sourced in Part 4.0. ↩

  2. Resting heart rate and heart-rate variability as proxies for cardiovascular and recovery status, and their use as early-warning trends: see the HRV/training-load literature and the device documentation discussed in Part 2.1. Optical-sensor data is best used as an individual trend, confirmed with calibrated devices and bloodwork. ↩

  3. Marker-specific interpretation (sensitive estradiol assay; prolactin and 19-nors; SHBG as an active carrier; cystatin-C vs. creatinine in muscular individuals; GGT vs. exercise-elevated AST/ALT; thyroid triad and GH-accelerated T4→T3): cross-referenced from [[Part 2.0 - Medical Screening ↩

Graph View

Backlinks